Tag: poster

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

Orrön Energy AB (”Orrön Energy” eller ”Bolaget”) meddelar att Bolaget har ingått ett avtal med Cloudberry Clean Energy ASA (”Cloudberry”) om att kombinera Bolagets nordiska plattform och organisation inom förnybar energi, exklusive vindkraftsparken Karskruv, med Cloudberry (”Transaktionen”), och därigenom skapa en ledande nordisk oberoende elproducent (”IPP”). Som ersättning för Transaktionen kommer Orrön Energy att erhålla 27,01 procent av aktierna i ett större Cloudberry, och därmed bli dess största aktieägare. Dessutom kommer utestående lån inklusive upplupen ränta som per utgången av 2025 uppgick till cirka 93 MEUR sammanlagt att regleras eller övertas av Cloudberry, och Orrön Energy kommer att erhålla 4,2 MEUR i kontant köpeskilling. Orrön Energy kommer att ta en aktiv roll i Cloudberrys framtida tillväxt genom styrelserepresentation och bidra med erfarenhet av värdeskapande från Lundin-gruppen till den sammanslagna verksamheten. Orrön Energy kommer fortsatt att äga vindkraftsparken Karskruv och den storskaliga projektverksamheten i Europa inom datacenter, solenergi och batterier.

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Media Release

COPENHAGEN, Denmark; June 13, 2026

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

Access the segment here